The Missing Inc(RNA) between the pancreatic β-cell and diabetes

Vasumathi Kameswaran and Klaus H. Kaestner*

Department of Genetics and Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

INTRODUCTION

Recent technological advances in the field of genome sequencing have paved the way for a new appreciation of non-coding RNAs in gene regulation. Ultra high-throughput transcriptome analyses have revealed that the vast majority of the genome is transcribed, with two-thirds of the human genome covered by processed transcripts, of which only a small fraction (<2%) is translated into proteins (Djebali et al., 2012). The identification of several common genomic and functional features of these untranslated RNAs has led to their categorization into various classes of non-coding RNAs. One such class that has been the focus of extensive research is that of long non-coding RNAs (lncRNAs).

lncRNAs are defined as transcripts longer than 200 bp that lack protein-coding potential (Guttman et al., 2009; Derrien et al., 2011; Batista and Chang, 2013; Fatica and Bozzoni, 2014). Like messenger RNAs, lncRNAs typically have multiple exons, are processed using canonical splice sites, and may exist as several isoforms (Ponjavic et al., 2007; Cabili et al., 2011; Derrien et al., 2012). In contrast to mRNAs, lncRNAs preferentially display nuclear localization, consistent with their proposed function in chromatin organization and regulation of gene expression (Khalil et al., 2009; Zhao et al., 2010; Derrien et al., 2012; Guttmann and Rinn, 2012; Rinn and Chang, 2012; Fatica and Bozzoni, 2014).

Similar to protein-coding genes, lncRNA-encoding genes are marked by chromatin signatures typical of active transcription in the cell types where they are expressed, consisting of H3K4me3 (trimethylated lysine 4 in histone H3) at the promoter, followed by H3K36me3 along the transcribed regions (so-called “K4–K36 domains”; Guttman et al., 2009; Khalil et al., 2009; Cabilio et al., 2011; Guttmann and Rinn, 2012; Rinn and Chang, 2012). While lncRNA exons display weaker evolutionary conservation than those of protein-coding genes, there is evidence of positive selection for a subset of lncRNAs, which may be driven by constraints to maintain secondary structure required for functional interactions with their targets (Ponjavic et al., 2007; Guttmann et al., 2009; Cabilio et al., 2011; Ulitsky et al., 2011; Derrien et al., 2012). In contrast, the promoters of lncRNAs are as highly conserved as those of protein-coding genes (Carninci et al., 2005; Ponjavic et al., 2007; Guttmann et al., 2009; Derrien et al., 2012; Batista and Chang, 2013). Despite their overall lower expression levels, lncRNAs exhibit a higher degree of tissue specificity compared to average protein-coding genes (Mercer et al., 2009; Cabilio et al., 2011; Derrien et al., 2012; Batista and Chang, 2013; Fatica and Bozzoni, 2014).

Through numerous studies, several general principles of IncRNA function have emerged. LncRNAs have been shown to function both in cis, i.e., locally close to the site of their production, and in trans, i.e., at sites on other chromosomes. LncRNAs have been proposed to act as scaffolds for chromatin modifiers, block-ers of transcription, antisense RNAs, microRNA sponges, protein decoys, and enhancers (Cech and Steitz, 2014; Fatica and Bozzoni, 2014). In fact, the act of transcription of a lncRNA itself can interfere with the regulatory function of a regulatory DNA sequence, as exemplified in yeast (Martens et al., 2004) and in mammalian imprinting (Latos et al., 2012). As a result of their diverse functions in multiple tissues, mis-regulation of lncRNAs can lead to failure of normal development and, consequently, to disease. Mammalian chromatin modifiers such as the repressive polycomb complexes often lack their own specific DNA-binding domains but instead contain RNA-binding elements. LncRNAs can play critical roles in directing these repressive chromatin modifying complexes to their target regions (Bernstein and Allis, 2005; Rinn et al., 2007; Zhao et al., 2010). One such example is the Foxf1-adjacent, non-coding developmental regulatory RNA (Fendrr), a lncRNA that

Diabetes mellitus represents a group of complex metabolic diseases that result in impaired glucose homeostasis, which includes destruction of β-cells or the failure of these insulin-secreting cells to compensate for increased metabolic demand. Despite a strong interest in characterizing the transcriptome of the different human islet cell types to understand the molecular basis of diabetes, very little attention has been paid to the role of long non-coding RNAs (lncRNAs) and their contribution to this disease. Here we summarize the growing evidence for the potential role of these lncRNAs in β-cell function and dysregulation in diabetes, with a focus on imprinted genomic loci.

Keywords: IncRNA, β-cell biology, diabetes mellitus, imprinting control region (ICR), MEG3
interacts with the polycomb repressive complex 2 (PRC2) and is critical for heart development and function (Grote et al., 2013). Similarly, the well-characterized HOTAIR lncRNA, which is transcribed from the HOXC locus, is highly upregulated in primary breast tumors and was shown to function through the silencing of tumor suppressor genes in a PRC2-dependent manner [Gupta et al., 2010; See Maass et al. (2014) for a list of lncRNAs currently implicated in human diseases]. Taken together, these features suggest that lncRNAs and other non-coding RNA species may play an essential role in defining organismal complexity (Mattick and Makunin, 2006; Taft et al., 2007).

These findings raise the possibility that lncRNAs and other non-coding RNAs may be exciting molecular candidates to account for the unresolved genetic risk in complex diseases such as diabetes (Medici et al., 1999; Hyttinen et al., 2003). Diabetes mellitus represents a group of metabolic diseases that result in impaired glucose homeostasis. In the case of type 1 diabetes (T1D), metabolic impairment is the result of autoimmune destruction of insulin-producing pancreatic β-cells. In type 2 diabetes (T2D), the most prevalent form of the disease, the defect in glucose metabolism is the result of decreased sensitivity of peripheral tissues to insulin action, accompanied by failure of β-cells to compensate for the increased metabolic demand (Zimmet et al., 2001). Together, these diseases affect over 25 million Americans and account for $176 billion in healthcare costs per year in the US alone (Association, 2013), necessitating the pursuit of more effective and personalized treatments.

Significant efforts have been made to attain a better understanding of the causes of diabetes at the molecular level. Linkage analysis of affected families led to the successful identification of causal gene mutation in several rare, Mendelian forms of the disease (Fajans et al., 2001; O’Rahilly, 2009). However, large-scale efforts to identify DNA variants associated with more common forms of diabetes through genome-wide association studies (GWAS) have predominantly identified candidate variants that lie in non-coding regions and with as yet unknown functions (McCarthy, 2010). Thus, to improve our current understanding of the molecular basis of diabetes mellitus and to develop better treatment strategies, we need to carefully characterize the transcriptome of pancreatic β-cells, with a focus on elucidating the functions of non-coding transcripts. In this review, we present a summary of recent evidence for a role of lncRNAs in the regulation of β-cell function and their potential contribution to the pathogenesis of diabetes.

β-CELL IncRNAs

The most comprehensive catalog of human lncRNAs expressed in β-cells published thus far is that by Morán et al. (2012). In this study, the authors profiled whole islet and FACS-sorted β-cells and identified 1,128 distinct transcripts that displayed many of the typical properties of lncRNAs described above, including the “K4–K36” histone modification domains, lack of protein-coding potential, and non-uniform expression levels among tissues. Most notably, the lncRNAs identified were roughly five times more islet-specific compared to general protein-coding genes, and the vast majority had orthologous genes in the mouse genome. Ku et al. (2012) similarly characterized mouse islet- and β-cell-specific transcripts and identified 1,359 high-confidence lncRNAs with several of the aforementioned properties. Using high-throughput transcriptome analysis of sorted human islets, lncRNAs expressed in α-cells have also been identified (Bramswig et al., 2013).

Of particular interest was the fact that lncRNAs were often found in proximity to critical islet-specific transcription factors (Ku et al., 2012; Morán et al., 2012). Thus, protein-coding genes adjacent to islet-enriched lncRNAs were also more likely to be islet-specific than the average protein-coding gene (Morán et al., 2012). This correlation has led to the suggestion that lncRNAs and nearby protein-coding genes share common regulatory elements. Indeed, lncRNAs were often found in large regions of open chromatin that were uniquely associated with protein-coding genes expressed highly in islets (Gaulton et al., 2010).

The temporal expression of islet lncRNAs has also been studied by Morán et al. (2012) in human embryonic pancreas as well as in a stepwise in vitro β-cell differentiation model using human embryonic stem (ES) cells (developed by Kroon et al., 2008). Unlike some lncRNAs that are known to be critical to early stages of embryonic development (Guttman et al., 2011; Grote et al., 2013), the expression of a majority of islet lncRNAs identified in this study (Morán et al., 2012) is restricted to differentiated, mature endocrine cells. The orthologous mouse lncRNAs (e.g., Mi-Lnc80) exhibit similar cell- and stage-specific expression.

The characteristics of these islet lncRNAs imply a role for these RNAs in mature β-cell function. To test this hypothesis, Morán et al. (2012) used short hairpin RNAs (shRNAs) to suppress the activity of one such lncRNA transcript in the human EndoC-βH1 β-cell line (Ravassard et al., 2011). From a panel of known islet-specific transcripts, the authors identified GLIS3 as a downstream target of HI-LNC25, a lncRNA that shares a regulatory domain with MAFB. Variants at the GLIS3 locus are associated with different risks for T1D (Barrett et al., 2009), elevated fasting glucose levels (Dupuis et al., 2010), as well as T2D (Cho et al., 2012). Loss-of-function studies suggest that GLIS3 encodes a transcription factor critical for regulating the expression of insulin and several key islet-transcription factors, and may confer risk for both T1D and T2D by resulting in diminished β-cell numbers and by promoting the formation of a pre-apoptotic splice variant of the protein Bim (Kang et al., 2009; Nogueira et al., 2013; ZeRuth et al., 2013). However, the shRNA-mediated decrease in GLIS3 mRNA levels had no impact on glucose-stimulated insulin secretion or insulin transcript levels in the transduced EndoC-βH1 β-cell line, possibly because this cell line does not recapitulate all aspects of β-cell function in vivo. Additionally, only a minor fraction of β-cell expressed lncRNAs was responsive to elevated glucose levels in human islets.

As previously noted, several risk variants for common forms of diabetes identified by GWAS do not change the protein-coding potential of known genes, suggesting that they might affect as yet unidentified regulatory elements (McCarthy, 2010). Using a computational tool known as MAGENTA to search for enrichment of genetic associations in a predefined set of genes (Segrè et al., 2010), Morán et al. (2012) determined that the islet lncRNA genes identified in their study were in fact highly enriched for risk alleles associated with T2D and related phenotypes, further underscoring the need to interrogate the function of these RNAs in β-cell biology.
Overall, these studies highlighted lncRNAs as a major component of the β-cell transcriptome that is cell-type-specific, developmentally regulated, and evolutionarily conserved with strong associations to disease risk. However, it still remains to be determined how these lncRNAs may contribute to β-cell function, and if their mis-regulation may play a role in diabetes. Their expression in EndoC-βH1 cells and mouse islets provides additional platforms to evaluate their function in a systematic and comprehensive manner. Future studies will also need to address the question of whether the lncRNAs identified thus far act in cis (on neighboring islet protein-coding genes) or in trans to exert their function.

**IMPRINTING**

Some of the best characterized lncRNAs to date were first uncovered in early studies of imprinting and dosage compensation of the X-chromosome (Brannan et al., 1996; Brown et al., 1991; Fatica and Bozzoni, 2014). Imprinting refers to the biased expression of genes depending on the parental origin of the chromosome. This process is tightly regulated, typically through epigenetic modifications such as DNA methylation at cis-acting elements known as “imprinting control regions” (ICRs), to establish and maintain mono-allelic expression of specific genes (Thorvaldsen and Bartolomei, 2007). Methylation at the ICRs is maintained despite active demethylation and dynamic reprogramming in the newly formed zygote, and is only altered during establishment of methylation pattern in a sex-specific manner during primordial germ cell development (Bartolomei and Ferguson-Smith, 2011). Imprinted loci are generally found in large clusters, where both maternally- and paternally expressed genes are interspersed. Frequently, the protein-coding genes are expressed from one parent allele, while non-coding genes are expressed from the other (Barlow, 2011). LncRNAs play an essential role in the regulation of mono-allelic expression, either by acting in cis as an antisense molecule to block the transcriptional machinery, or by directly recruiting repressive chromatin modifiers to silence reciprocally expressed genes (Lee and Bartolomei, 2013).

While imprinting is most extensively studied in the context of fetal development, tissue-specific regulation in adult tissues has also been observed (Barlow, 2011; Lee and Bartolomei, 2013). As a result, several imprinted genes are also implicated in human diseases that arise from somatic tissues. One such example is that of the maternally expressed adipose tissue transcription factor, KLF14 (Parker-Katiaere et al., 2007), which is associated with risk for both T2D and high-density lipoprotein disorders (Teslovich et al., 2010; Voight et al., 2010; Small et al., 2011). Perhaps the functionally haploid nature of these loci results in their increased likelihood to be associated with susceptibility to disease, as mutations in these genes, when found on the maternal chromosome that is expressed, cannot be “covered” by the gene from the other, silenced paternal allele. This may be particularly true for metabolic disorders, as several imprinted genes encode dosagesensitive proteins related to growth factors and energy metabolism. Interestingly, several risk variants for type 1 and type 2 diabetes identified through GWAS are located in imprinted loci including KCNQ1, MEG3, PLAGL1, and GRB10. A few of these are discussed below in the context of islet and β-cell function.

**MEG3**

MEG3, also known as CDKN1C antisense RNA (CASC2), is a maternally expressed lncRNA that has been shown to play a role in the regulation of both human and mouse β-cells. MEG3 is highly expressed in human and mouse β-cells and contains three paternally expressed protein-coding genes, DLK1, RTL1, and DIO3. DLK1 is a non-canonical Notch ligand that is expressed in many embryonic tissues (Falis et al., 2012) and is a well-established negative regulator of adipocyte differentiation (Simas and Sul, 1993; Mitterberger et al., 2012; Abdallah et al., 2013). DLK1 is highly expressed in human and mouse β-cells (Torrehave et al., 1996; Dorrell et al., 2011; Appelbe et al., 2013). While DLK1 was demonstrated to be stimulated by growth hormone and prolactin expression in rat islets, including during pregnancy, it is not directly responsible for the mitogenic effects of these hormones on islets (Carlsson et al., 1997; Friedrichsen et al., 2003). Additionally, loss of expression of Dlk1 in unchallenged mouse β-cells does not cause any observable phenotype (Appelbe et al., 2013). Rtl1 (Retrotransposon-like 1) is critical for normal placental development and its loss results in severe developmental defects and late-fetal lethality (Sekita et al., 2008).

The maternally expressed genes are all non-coding RNAs, consisting of the lncRNA, Maternally Expressed Gene 3 (MEG3, known as Gtl2 in mice), as well as a large cluster of microRNAs (miRNAs) and snoRNAs (Schmidt et al., 2000; Seitz et al., 2004; da Rocha et al., 2008). In several tissues, including human islets, the non-coding RNAs are all derived from a single transcript that initiates from the MEG3 promoter (Tierling et al., 2006; da Rocha et al., 2008; Kameswaran et al., 2014).

Reciprocal imprinting is established by methylation of two differentially methylated regions (DMRs) on the paternal allele, one located ~13 kb upstream of the MEG3 transcription start site (IG-DMR), and the other overlapping with the promoter of the MEG3 poly cistronic transcript (MEG3-DMR; Figure 1). While the IG-DMR is the primary ICR for this imprinted cluster, the MEG3-DMR is also critical to regulating and maintaining imprinting at this region (Kagami et al., 2010). Failure to maintain imprinting at this locus can lead to either maternal or paternal uniparental disomy (UPD) of chromosome 14, which causes distinct and severe developmental disorders (Kagami et al., 2008).

Increased methylation of the MEG3-DMR and related loss of MEG3 expression has been observed in several human cancers, such as pituitary and renal cell cancers and multiple myeloma (Zhao et al., 2005; Kawakami et al., 2006; Benetatos et al., 2008) to name a few (further reviewed by Benetatos et al., 2011). These studies, coupled with in vitro experiments, suggest that MEG3 functions as a tumor suppressor by activating p53, in a manner dependent upon the secondary structure of the MEG3 RNA (Zhou et al., 2007, 2012). Furthermore, decreased expression of MEG3 and hypermethylation of the DMRs may single-handedly explain the subtle phenotypic differences between induced pluripotent stem cells (iPSCs) and ES cells, such as the decreased efficiency in generating chimeric mice from iPSCs (Stadtfeld et al., 2010).
Kameswaran and Kaestner lncRNAs in diabetes

**FIGURE 1** Proposed model of imprinting at the DLK1–MEG3 locus: the DLK1–MEG3 imprinted region contains a primary ICR (IG-DMR) and a secondary (MEG3–DMR) ICR that overlaps with the promoter of the MEG3. Both ICRs are paternally methylated. In mouse ES cells, the MEG3 lncRNA is believed to direct PRC2 mediated silencing of Dlk1 (Zhao et al., 2010).

et al., 2014). Additionally, a single nucleotide polymorphism (SNP) (rs941576) located in an intron of MEG3 was found to be associated with T1D, with the risk allele being transmitted more frequently from the father than the mother of the affected offspring (Wallace et al., 2010). Overall, these examples provide compelling evidence for the importance of MEG3 and the regulation of this imprinted region in several diseases. Despite the strong disease association of this lncRNA, and the fact that genes in this imprinted cluster are very highly expressed in human β-cells (Dorrell et al., 2011; Kameswaran et al., 2014), there are currently no postulated mechanisms for its potential role in β-cell function and diabetes pathogenesis.

Recent studies have suggested that similar to other nuclear lncRNAs, MEG3 also directly interacts with the PRC2 complex in ES cells to guide the repressive histone modification mark H3K27me3 to its target sites (Zhao et al., 2010; Kaneko et al., 2014). One study identified Dlk1 as a direct target of the Meg3-PRC2 complex in mouse ES cells (Figure 1), although this finding could not be replicated in MEG3-expressing human iPSCs, where MEG3 was found to function in trans (Zhao et al., 2010; Kaneko et al., 2014). A careful characterization of MEG3-PRC2 complex targets in adult pancreatic islets will provide better insights into the role of this lncRNA in β-cell function.

**KCNQ1 LOCUS**

The KCNQ1 gene, encoding a voltage-gated potassium channel, has been of great interest to the β-cell biology field due to its strong disease association. The gene is located in an imprinted locus on human 11p15.5, adjacent to another independently regulated imprinted locus, H19–IGF2. This region was implicated as a molecular candidate for Beckwith–Wiedemann syndrome (BWS), a disorder characterized by prenatal macrosomia, predisposition for tumor development and frequently, hyperinsulinemic hypoglycemia (Lee et al., 1997, 1999; Hussain et al., 2005). This imprinted region consists of several conserved, maternally expressed protein-coding genes, such as the cell cycle inhibitor CDKN1C, and a paternally expressed antisense lncRNA, KCNQ1 overlapping transcript1 (KCNQ1OT1; Monk et al., 2006). Loss of imprinting in this locus can lead to the suppression of CDKN1C, which is sufficient to cause re-entry of adult human β-cells into the cell cycle (Avrahami et al., 2014).

Imprinting of this region is maintained by a maternally methylated ICR, known as the KvDMR, which is also the promoter for KCNQ1OT1 (Figure 2). To maintain appropriate monoallelic expression of imprinted genes in this locus, the KvDMR is hypomethylated on the paternal allele, leading to expression of the KCNQ1OT1 lncRNA and subsequent repression of the maternal, protein-coding genes on the same allele (Fitzpatrick et al., 2002; Ideraabdullah et al., 2008), possibly by facilitating intra-chromosomal looping to direct the repressive PRC2 complex to their promoter (Figure 2; Zhao et al., 2010; Zhang et al., 2014).

The KCNQ1 locus harbors at least two independently identified and replicated GWAS signals at SNPs located in the intron of the KCNQ1 gene (rs2237892), with one overlapping the KCNQ1OT1 lncRNA (rs231362; Unoki et al., 2008; Yasuda et al., 2008; Kong et al., 2009; Voight et al., 2010). Additional SNPs in this gene, such as rs2237895, are also reported to be associated with T2D risk in specific ethnic populations (Unoki et al., 2008). While these SNPs are predicted to confer risk for diabetes only when maternally inherited (Kong et al., 2009), the risk alleles do

**FIGURE 2** Proposed model of imprinting at the KCNQ1 locus: the KCNQ1OT1 lncRNA is expressed from the paternally unmethylated KvDMR ICR, which is methylated on the maternal allele. Recent evidence suggests that KCNQ1OT1 can directly recruit the PRC2 complex and facilitate intra-chromosomal looping to the KCNQ1 promoter (Zhang et al., 2014).
not correlate with each other (Kong et al., 2009; Voight et al., 2010) and have opposing effects on docking of insulin granules (Rosengren et al., 2012).

To investigate how these T2D risk variants may affect allelic expression and imprinting of this region, Travers et al. (2013) correlated the risk SNP genotypes with DNA methylation and expression patterns of the imprinted genes in human fetal pancreas and adult islets. This study revealed that fetal samples homozygous for the rs2237895 risk allele had marginally increased methylation levels at the KvDMR region. As this was not observed in the adult, these results suggest that effects of the risk allele are likely to be established during early stages of islet development, as KCNQ1 and KCNQ1OT1 are only imprinted in fetal but not adult tissues (Monk et al., 2006; Travers et al., 2013). Overall, this study proposes a model whereby each risk allele for the rs2237895 SNP leads to increased methylation of the KvDMR, and consequently, decreased expression of KCNQ1OT1. However, there was no observable difference in KCNQ1 or KCNQ1OT1 expression in samples used for this study. On the contrary, KCNQ1OT1 transcript levels have been shown to be significantly elevated in T2D islets (where SNP genotype was not determined; Morán et al., 2012), which parallels an overall decrease in methylation at several tested CpGs near the KCNQ1 gene (Dayeh et al., 2014). Thus, the interpretation of variants to disease pathology at this region has been contradictory and challenging. Nevertheless, the regulation of this locus and the IncRNA KCNQ1OT1 remains relevant to β-cell biology and T2D pathogenesis.

**H19–IGF2 locus**

The H19–IGF2 locus resides adjacent to the KCNQ1 region on human 11p15.5. The region consists of the paternally expressed insulin-like growth factor 2 (IGF2) gene and maternally expressed H19 IncRNA (Brannan et al., 1990; DeChiara et al., 1991). The IGF2 protein functions as a growth factor essential for embryonic development (DeChiara et al., 1990), whereas H19 may function as a tumor suppressor (Hao et al., 1993). Imprinting at this locus is maintained by an ICR, which is selectively methylated on the paternal allele. The insulin protein, CCCTC-binding factor (CTCF), binds to critical regulatory regions in the unmethylated ICR on the maternal allele, thus blocking access of downstream enhancers to the IGF2 promoter (Figure 3; Stadnick et al., 1999; Bell and Felsenfeld, 2000; Engel et al., 2004).

Loss of methylation at the H19/IGF2 ICR results in short body length and low birth weight, both in rodent models (DeChiara et al., 1990) as well as in humans, such as patients with Silver-Russell syndrome, a developmental disorder characterized by intrauterine and postnatal growth retardation (Gicquel et al., 2005). This has also been observed in humans who were periconceptually exposed to famine (Heijmans et al., 2008). There is growing evidence that intra-uterine exposure to malnutrition can predispose the offspring to metabolic complications including β-cell dysfunction and diabetes later in life (Ravelli et al., 1998; Roseboom et al., 2006). This theory is commonly referred to as the “thrifty phenotype hypothesis” (Hales, 2001) and is thought to be mediated primarily through environmentally induced epigenetic changes to key metabolic regulators (Park et al., 2008; Bramswig and Kaestner, 2012). However, first and second generation progeny of mice exposed to gestational diabetes were found to have impaired glucose tolerance with hypermethylation of the H19 ICR in islets (Ding et al., 2012). These contradicting observations may be a result of different nutrient availability that the developing fetus was exposed to, as well as the varying lengths of exposure. The above studies suggest that the H19–IGF2 locus is highly responsive to these changes in the intrauterine milieu and may represent a prognostic marker of metabolic complications later in life.

Hypermethylation of the H19–IGF2 ICR has been observed in some cases of BWS (Ohlsson et al., 1993), as well as in focal congenital hyperinsulinism (FoCHI), a glucose metabolism disorder characterized by unbridled insulin secretion from hyperplastic islet cells and consequent hypoglycemia (de Lonlay et al., 1997). Increased methylation at this ICR would be predicted to result in decreased H19 expression, loss of imprinting at this region and a concomitant increase in IGF2 expression. Although overexpression of IGF2 in mouse β-cells recapitulates the FoCHI phenotype (Devedjian et al., 2000), IGF2 expression was variable in human FoCHI lesions (Fournet et al., 2001). On the contrary, H19 transcript levels were consistently down-regulated in these cells, suggesting that H19 may have an important regulatory role in restraining islet-proliferation. This hyperproliferative phenotype, accompanied by suppression of H19 has also been reported in Wilms’ tumor (Cui et al., 1997). Taken together, the H19 IncRNA may function as a critical regulator of β-cell function and proliferation either on its own or indirectly through the regulation of IGF2 levels.
**ZAC–HYMAI LOCUS**

Transient neonatal diabetes (TNDM) is a rare form of diabetes mellitus characterized by hyperglycemia and low insulin levels within the first year of birth (Temple et al., 2000). This form of diabetes is distinct from T1D as there is no evidence for autoimmunity (Abramowicz et al., 1994; Shield et al., 1997). Although it usually resolves by 2 years of age, children with TNDM are at a higher risk of developing T2D later in life (Temple et al., 2000). The molecular cause of this disease was identified to be abnormal imprinting of chromosome 6q24, which encompasses the cell cycle regulator, ZAC/PLAGL1, and the lncRNA, HYMAI (Abramowicz et al., 1994; Arima et al., 2000; Gardner et al., 2000; Kamiya et al., 2000; Mackay et al., 2002). Both ZAC and HYMAI share a common imprinted promoter (P1 in Figure 4), which also serves as the ICR, and are expressed from the paternal allele (Arima et al., 2000; Mackay et al., 2002). However, tissue-specific usage of an alternative promoter (P2 in Figure 4) that drives biallelic expression of ZAC has also been reported (Valleley et al., 2007).

ZAC encodes a zinc finger protein that regulates apoptosis and cell cycle arrest (Spengler et al., 1997). The protein is expressed at very high levels in insulin-producing cells in the human fetal pancreas, but not adult islets (Du et al., 2011). ZAC can also function as a transcriptional activator of CDKNIC and KCNQ1OT1 (Arima et al., 2005). ZAC is believed to control the induction of the pituitary adenylate cyclase-activating polypeptide (PACAP), a strong activator of glucose-stimulated insulin secretion (Yada et al., 1994; Giani et al., 1999). These features of the ZAC gene make it a strong candidate for the pathogenesis of TNDM. However, the mechanism of imprinting and the function of HYMAI in the context of TNDM have yet to be established.

**MALAT1, AN ABUNDANT IncRNA**

The metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a highly conserved IncRNA that is mis-regulated in several tumors (Ji et al., 2003; Gutschner et al., 2013). MALAT1 is very abundantly expressed (higher than many housekeeping genes) in multiple cell types, including the pancreas (Ji et al., 2003) and in purified human α- and β-cells (Dorrell et al., 2011). Additionally, MALAT1 is encoded within an active enhancer cluster with several binding sites for islet-transcription factors (Pasquali et al., 2014), making this an intriguing candidate for gene regulation in human islets.

Metastasis-associated lung adenocarcinoma transcript 1 has several interacting partners through which it may mediate its function. One such interacting partner is DGCR8, a double-stranded RNA binding protein that together with Drosha mediates miRNA bioprocessing (Macias et al., 2012). MALAT1 was found to be bound to Argonaute (Ago), the primary effector of miRNA function in HeLa cells (Weinmann et al., 2009). MALAT1 was also found to be associated with Ago in human islets, suggesting that this lncRNA may be regulated by miRNAs in human cells (Kameswaran et al., 2014). In fact, we discovered several sequences that consisted of miRNAs fused to MALAT1 while assaying miRNAs and their targets that were bound to Ago in human islets. These chimeric reads were the result of ligation of two adjacent RNA species present in the RISC complex with Ago (Helwak et al., 2013), and proved that MALAT1 is regulated by several miRNAs in human islets (Kameswaran et al., 2014).

Metastasis-associated lung adenocarcinoma transcript 1 can also regulate gene expression through its association with different nuclear sub-compartments (Hutchinson et al., 2007; Yang et al., 2011; Gutschner et al., 2013). One example of this is MALAT1 localization in nuclear speckles, which are nuclear domains where splicing factors are stored and post-transcriptionally modified (Hutchinson et al., 2007; Mao et al., 2011). Through the modification of critical splicing factors, MALAT1 has been shown to contribute to alternative splicing (Tripathi et al., 2010). However, despite the abundance of this lncRNA and the early suggestions of its function from in vitro studies, mice lacking MALAT1 displayed no obvious phenotype in the absence of additional pathological stressors and exhibit largely normal nuclear speckle formation and alternative splicing patterns (Eißmann et al., 2012; Nakagawa et al., 2012; Zhang et al., 2012). Thus, the role of this lncRNA remains to be determined.

**PERSPECTIVE**

The exciting discovery of IncRNAs and the growing recognition of their involvement in human pathogenesis have added a new level of complexity to our understanding of gene regulation. However, due to the range of sequencing and bioinformatic tools currently available, the rate of discovery of new IncRNAs has surpassed our ability to examine their function. This gap between IncRNA gene discovery and function currently holds true in the field of β-cell biology as well, necessitating the systematic analysis of mouse and human islet IncRNAs identified to date (Ku et al., 2012; Morán et al., 2012). Factors such as overlap between the human and mouse α- and β-cell IncRNA complements (Ku et al., 2012; Morán et al., 2012;
Bramswig et al., (2013), degree of conservation, expression, associated protein-coding genes, and relative distance from GWAS SNP variants may be good early predictors of important IncRNAs. However, these parameters alone may underestimate other essential candidates, as some IncRNAs exhibit low primary sequence conservation despite crucial function (Nesterova et al., 2001), or, conversely, a dispensable function despite high sequence conservation and expression (Zhang et al., 2012). These observations emphasize the need for careful loss-of-function experiments in appropriate model systems induced by metabolic and/or inflammatory challenges to clearly understand the function of these IncRNAs. Although many of the human β-cell IncRNAs are expressed in the EndoC-B1 cell line that somewhat resembles human β-cells in vitro (Ravassard et al., 2011), targeted deletion or inhibition in mouse and human islets may be necessary in some cases to reveal their function, as seen in the example of HI-LNC25 discussed above (Morán et al., 2012).

While the loss-of-function of even abundant IncRNAs such as MALAT1 may sometimes result in a lack of phenotype (Eißmann et al., 2012; Nakagawa et al., 2012; Zhang et al., 2012), lessons from the miRNA field suggest that additional physiological and environmental stressors may be necessary to truly elucidate the function of these non-coding RNAs (Mendell and Olson, 2012). Additionally, in order to study the role of IncRNAs in the context of loss-of-function, a careful analysis of the genomic location of the IncRNAs may be required to evaluate the best method of gene silencing, as targeted recombination may result in disruption of overlapping protein-coding transcripts or their regulatory domains, further confounding data interpretation.

Given the broad range of human diseases that IncRNAs are now associated with, it is perhaps not surprising that there is growing evidence for their role in β-cell function and diabetes pathogenesis. Revealing their function will undoubtedly lead to a new wave of exciting targets to explore for therapeutic development.

ACKNOWLEDGMENTS
We apologize to colleagues whose work we could not cite due to the limited scope of this review. We thank Dr. John Le Lay and other members of the Kaestner lab for useful discussions and suggestions on this manuscript. Related work in the Kaestner lab was supported through NIDDK grant R01-DK088383.

REFERENCES
Abdallah, B. M., Beck-Nielsen, H., and Gaster, M. (2013). FA1 induces proinflammatory and anti-adipogenic pathways/markers in human myotubes established from lean, obese, and type 2 diabetic subjects but not insulin resistance. *Front. Endocrinol. (Lausanne)* 4:45. doi: 10.3389/fendo.2013.00045
Abramowicz, M. I., Andrien, M., Dupont, E., Dorchy, H., Parma, J., Duprez, L., et al. (2002). Isodisomy of chromosome 6 in a newborn with methylmalonic acidemia and agenesis of pancreatic beta cells causing diabetes mellitus. *J. Clin. Invest. 94, 418–421.* doi: 10.1172/JCI17339
Appelbe, O. K., Yevtodiyenko, A., Muniz-Talavera, H., and Schmidt, J. V. (2013). Conditional deletions refine the embryonic requirement for Dlk1. *Mol. Cell. Biol.* 130, 143–159. doi: 10.1061/medi.2012.09.010
Arima, T., Drewell, R. A., Oshimura, M., Wake, N., and Surani, M. A. (2000). A novel imprinted gene, HVM1, is located within an imprinted domain on human chromosome 6 containing ZAC. *Genomics* 67, 248–255. doi: 10.1006/geno.2000.6266
Arima, T., Kamikihara, T., Hayashida, T., Kato, K., Inoue, T., Shirayoshi, Y., et al. (2005). ZAC, LIT1 (KCNQ1OT1) and p57Kip2 (CDKN1C) are in an imprinted gene network that may play a role in Beckwith-Wiedemann syndrome. *Nucleic Acids Res.* 33, 2650–2660. doi: 10.1093/nar/gki555
Association, A. D. (2013). Economic costs of diabetes in the U.S. in 2012. *Diabetes Care* 36, 1033–1046. doi: 10.2337/dc12-2625
Avrahami, D., Li, C., Yu, M., Jiao, Y., Zhang, J., Naji, A., et al. (2014). Targeting the cell cycle inhibitor p57Kip2 promotes adult human β cell replication. *J. Clin. Invest.* 124, 670–674. doi: 10.1172/JCI69519
Barlow, D. P. (2011). Genomic imprinting: a mammalian epigenetic discovery model. *Annu. Rev. Genet.* 45, 379–403. doi: 10.1146/annurev-genet-110410-132459
Barrett, J. C., Clayton, D. G., Concannon, P., Akolkar, B., Cooper, J. D., Erlich, H. A., et al. (2009). Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. *Nat. Genet.* 41, 703–707. doi: 10.1038/ng.381
Bartolomei, M. S., and Ferguson-Smith, A. C. (2011). Mammalian genomic imprinting. *Cold Spring Harb. Perspect. Biol.* 3:a002592. doi: 10.1101/cshperspect.a002592
Bartolomei, M. S., Zernel, S., and Tåghman, S. M. (1991). Parental imprinting of the mouse H19 gene. *Nature* 351, 153–155. doi: 10.1038/351153a0
Batista, P. L., and Chang, H. Y. (2013). Long noncoding RNAs: cellular address codes for disease. *Cell* 152, 1298–1307. doi: 10.1016/j.cell.2013.02.012
Bell, A. C., and Felsenfeld, G. (2000). Methyltransferases of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. *Clin. Lymphoma Myeloma* 8, 171–175. doi: 10.3816/CLIM.2008.n.021
Benetatos, L., Vartholomatos, G., and Hatzimichael, E. (2011). MEG3 imprinted gene contribution in tumorigenesis. *Int. J. Cancer* 129, 773–779. doi: 10.1002/ijc.26052
Bernstein, E., and Allis, C. D. (2005). RNA meets chromatin. *Genes Dev.* 19, 1653–1665. doi: 10.1101/gad.1324305
Bramswig et al., 2013), degree of conservation, expression, and relative distance from GWAS SNP variants may be good early predictors of important IncRNAs. However, these parameters alone may underestimate other essential candidates, as some IncRNAs exhibit low primary sequence conservation despite crucial function (Nesterova et al., 2001), or, conversely, a dispensable function despite high sequence conservation and expression (Zhang et al., 2012). These observations emphasize the need for careful loss-of-function experiments in appropriate model systems induced by metabolic and/or inflammatory challenges to clearly understand the function of these IncRNAs. Although many of the human β-cell IncRNAs are expressed in the EndoC-B1 cell line that somewhat resembles human β-cells in vitro (Ravassard et al., 2011), targeted deletion or inhibition in mouse and human islets may be necessary in some cases to reveal their function, as seen in the example of HI-LNC25 discussed above (Morán et al., 2012).

While the loss-of-function of even abundant IncRNAs such as MALAT1 may sometimes result in a lack of phenotype (Eißmann et al., 2012; Nakagawa et al., 2012; Zhang et al., 2012), lessons from the miRNA field suggest that additional physiological and environmental stressors may be necessary to truly elucidate the function of these non-coding RNAs (Mendell and Olson, 2012). Additionally, in order to study the role of IncRNAs in the context of loss-of-function, a careful analysis of the genomic location of the IncRNAs may be required to evaluate the best method of gene silencing, as targeted recombination may result in disruption of overlapping protein-coding transcripts or their regulatory domains, further confounding data interpretation.

Given the broad range of human diseases that IncRNAs are now associated with, it is perhaps not surprising that there is growing evidence for their role in β-cell function and diabetes pathogenesis. Revealing their function will undoubtedly lead to a new wave of exciting targets to explore for therapeutic development.

REFERENCES
Abdallah, B. M., Beck-Nielsen, H., and Gaster, M. (2013). FA1 induces proinflammatory and anti-adipogenic pathways/markers in human myotubes established from lean, obese, and type 2 diabetic subjects but not insulin resistance. *Front. Endocrinol. (Lausanne)* 4:45. doi: 10.3389/fendo.2013.00045
Abramowicz, M. I., Andrien, M., Dupont, E., Dorchy, H., Parma, J., Duprez, L., et al. (1994). Isodisomy of chromosome 6 in a newborn with methylmalonic acidemia and agenesis of pancreatic beta cells causing diabetes mellitus. *J. Clin. Invest. 94, 418–421.* doi: 10.1172/JCI17339
Appelbe, O. K., Yevtodiyenko, A., Muniz-Talavera, H., and Schmidt, J. V. (2013). Conditional deletions refine the embryonic requirement for Dlk1. *Mol. Cell. Biol.* 130, 143–159. doi: 10.1061/medi.2012.09.010
Arima, T., Drewell, R. A., Oshimura, M., Wake, N., and Surani, M. A. (2000). A novel imprinted gene, HVM1, is located within an imprinted domain on human chromosome 6 containing ZAC. *Genomics* 67, 248–255. doi: 10.1006/geno.2000.6266
Arima, T., Kamikihara, T., Hayashida, T., Kato, K., Inoue, T., Shirayoshi, Y., et al. (2005). ZAC, LIT1 (KCNQ1OT1) and p57Kip2 (CDKN1C) are in an imprinted
da Rocha, S. T., Edwards, C. A., Ito, M., Ogata, T., and Ferguson-Smith, A. C. (2008). Genomic imprinting at the mammalian DLK1-Dio3 domain. Trends Genet. 24, 306–316. doi: 10.1016/j.tig.2008.03.011

Dayeh, T., Volkov, P., Saló, S., Hall, E., Nilsson, E., Olsson, A. H., et al. (2014). Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion. PLoS Genet. 10.e1004160. doi: 10.1371/journal.pgen.1004160

DeChiara, T. M., Efstratiadis, A., and Robertson, E. J. (1990). A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345, 78–80. doi: 10.1038/345078a0

de Lonlay, P., Fournet, J. C., Rahier, J., Gross-Morand, M. S., Poggi-Travert, F., Foussier, V., et al. (1997). Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinism hypoglycemia of infancy is specific of fetal adenaomatous hyperplasia and endorses partial pancreaticectomcy. J. Clin. Invest. 100, 802–807. doi: 10.1172/jci119994

Derrien, T., Johnson, R., Bussotti, G., Tanzer, A., Djebali, S., Tilgner, H., et al. (2012). The GENCODE v7 catalog of human long non-coding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 22, 1775–1789. doi: 10.1101/gr.132159.111

Devedjian, J. C., George, M., Casellas, A., Pujol, A., Visa, I., Pelegrin, M., et al. (2000). Transgenic mice overexpressing insulin-like growth factor II in beta cells develop type 2 diabetes. J. Clin. Invest. 105, 731–740. doi: 10.1172/JCI105656

Ding, G.-L., Wang, F.-F., Shu, J., Tian, S., Jiang, Y., Zhang, D., et al. (2012). Transgenerational insulin sensitivity changes in mouse islet induced by intrauterine hyperglycemia. Diabetes 61, 1133–1142. doi: 10.2373/db11-1314

Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., et al. (2012). Landscape of transcription in human cells. Nature 489, 101–108. doi: 10.1038/nature11233

Dorrell, C., Schug, J., Lin, C. F., Canaday, P. S., Fox, A. J., Smirnova, O., et al. (2011). Transcriptomes of the major pancreatic human cell types. Diabetesologia 54, 2832–2844. doi: 10.1111/j.1464-5491.2011.2283-5

Dupuis, J., Langenberg, C., Prokopenko, I., Saxena, R., Soranzo, N., Jackson, A. U., et al. (2010). New genetic loci implicated in fasting glucose homeostasis on type 2 diabetes risk. Nat. Genet. 42, 105–116. doi: 10.1038/ng.520

Duan, X., Rousseau, M., Ounissi-Benkalha, H., Marchand, L., Jetha, A., Parasekwas, S., et al. (2011). Differential expression pattern of ZAC in developing mouse and human pancreas. J. Mol. Histol. 42, 129–136. doi: 10.1007/s10735-011-9135-9

Efimova, M., Gutzsch, T., Hämmerle, M., Gunther, S., Caudron-Herger, M., Groß, M., et al. (2012). Loss of the abundant nuclear non-coding RNA MALAT1 – a paradigm for long noncoding RNA function in cancer. J. Mol. Med. 91, 791–801. doi: 10.1007/s00109-013-1028-y

Guttman, M., Amit, I., Garber, M., French, C., Lin, M. F., Feldser, D., et al. (2009). Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458, 223–227. doi: 10.1038/nature07872

Guttman, M., Donahghey, J., Carey, B. W., Garber, M., Grenier, J. K., Munson, G., et al. (2011). lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 477, 295–300. doi: 10.1038/nature10398

Guttman, M., and Rinn, J. L. (2012). Modular regulatory principles of large non-coding RNAs. Nature 482, 339–346. doi: 10.1038/nature10887

Hales, C. N. (2001). The thrifty phenotype hypothesis. Br. Med. Bull. 60, 5–20. doi: 10.1093/bmb/60.1.5

Hao, Y., Crenshaw, T., Mouton, T., Newcomb, E., and Tycko, B. (1993). Tumour-suppressor activity of H19 RNA. Nature 365, 764–767. doi: 10.1038/365764a0

Heijmans, B. T., Tobi, E. W., Stein, A. D., Putter, H., Blauw, G. J., Susem, E. S., et al. (2008). Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc. Natl. Acad. Sci. U.S.A. 105, 17046–17049. doi: 10.1073/pnas.0806560105

Helwak, A., Kudla, G., Dudnakova, T., and Tillorvey, D. (2013). Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 153, 654–665. doi: 10.1016/j.cell.2013.03.043

Hussain, K., Cosgrove, K. E., Shepherd, R. M., Luharia, A., Smith, V. V., Kassem, S., et al. (2005). Hyperinsulinism hypoglycemia in Beckwith-Wiedemann syndrome due to defects in the function of pancreatic beta-cell adenosine triphosphate-sensitive potassium channels. J. Clin. Endocrinol. Metab. 90, 4376–4382. doi: 10.1210/jc.2005-0158

Hutchinson, J. N., Ensminger, A. W., Clemson, C. M., Lynch, C. R., Lawrence, J. B., and Chess, A. (2007). A screen for nuclear transcripts identifies two linked noncoding RNA MALAT1–a paradigm for long noncoding RNA function in cancer. J. Mol. Med. 91, 791–801. doi: 10.1007/s00109-013-1028-y

Ideraabdullah, F. Y., Vigneau, S., and Bartolomei, M. S. (2008). Genomic imprinting mechanisms in mammals. Mutat. Res. 647, 77–85. doi: 10.1016/j.mrfmmm.2008.08.008

Ji, P., Diederichs, S., Wang, W., Boing, S., Metzger, R., Schneider, P. M., et al. (2003). MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22, 8031–8041. doi: 10.1038/sj.onc.1206928

Kagami, M., O’Sullivan, M. J., Green, A. J., Watabe, Y., Arisaka, O., Masawa, N., et al. (2010). The IG-DMR and the MEG3-DMR at human chromosome 14q32.2: hierarchical interaction and distinct functional properties as imprinting control centers. PLoS Genet. 6:e1000992. doi: 10.1371/journal.pgen.1000992

Kagami, M., Sekita, Y., Nishimura, G., Irie, M., Kato, F., Okada, M., et al. (2008). Deletions and epimutations affecting the human 14q32.2 imprinted region in individuals with paternal and maternal upd(14)-like phenotypes. Nat. Genet. 40, 237–242. doi: 10.1038/ng.2007.56

Kameswaran, V., Branswig, N. C., McKenna, L. B., Penn, M., Schug, J., Hand, N. J., et al. (2014). Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. Cell Metab. 19, 135–145. doi: 10.1016/j.cmet.2013.11.016
Kameswaran and Kaestner

In RNAs in diabetes

Kamiyama, M., Judson, H., Okazaki, Y., Kusakabe, M., Muramatsu, M., Takada, S., et al. (2000). The cell cycle control gene ZAC/PLAG1 is imprinted—a strong candidate gene for transient neonatal diabetes. *Hum. Mol. Genet.* 9, 453–460. doi: 10.1093/hmg/9.3.453

Kaneko, S., Bonasio, R., Saldanha-Meyer, R., Yoshida, T., Son, J., Nishino, K., et al. (2014). Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin. *Cell* 53, 290–300. doi: 10.1016/j.cell.2013.11.012

Kang, H. S., Kim, Y.-S., Zeutschl, G., Beak, J. Y., Gerrish, K., Klici, G., et al. (2009). Transcription factor Gli3, a novel critical player in the regulation of pancreatic β-cell development and insulin gene expression. *J. Cell. Biol.* 209, 6366–6379. doi: 10.1128/MCB.01259-09

Kawakami, T., Chano, T., Minami, K., Okabe, H., Okada, Y., and Okamoto, K. (2006). Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GLT2 in human renal cell carcinoma. *Hum. Mol. Genet.* 15, 821–830. doi: 10.1093/hmg/ddi001

Khalil, A. M., Guttman, M., Huarte, M., Garber, M., Raj, A., Rivea Morales, D., et al. (2012). Research resource: RNA-Seq reveals unique features of the pan-lncRNome. *Genome Res.* 23, 1469–1472. doi: 10.1101/gr.139301

Kong, A., Steinthorsdottir, V., Masson, G., Thorleifsson, G., Sulem, P., Besenbacher, S., et al. (2009). Parental origin of sequence variants associated with complex traits. *Nat. Genet.* 41, 821–830. doi: 10.1038/ng.380

Lee, M. P., Hu, R. J., Johnson, L. A., and Feinberg, A. P. (1997). Human ZAC/PLAGL1 is imprinted—strong evidence for selection within long noncoding RNAs. *Cell* 90, 5203–5208. doi: 10.1016/S0092-8674(00)81625-7

Mao, Y.-S., Zhang, B., and Spector, D. L. (2011). Biogenesis and function of nuclear long noncoding RNAs in health and disease. *Trends Genet.* 27, 556–563. doi: 10.1016/j.tig.2011.05.006

Mittreger, M. C., Lechner, S., Mattesich, M., Kaiser, A., Probst, D., Wenger, N., et al. (2012). DLK1(PREF1) is a negative regulator of adipogenesis in CD105+/CD90+/CD34+/CD31+/FABP4+ adipose-derived stromal cells from subcutaneous abdominal fat pads of adult women. *Stem Cell Res.* 34, 35–48. doi: 10.1016/j.scr.2012.04.001

Mun, D., Arnaud, P., Apostolidou, S., Hills, F. A., Kelsey, G., Stanier, P., et al. (2006). Limited evolutionary conservation of imprinting in the human placenta. *Proc. Natl. Acad. Sci. U.S.A.* 103, 6623–6628. doi: 10.1073/pnas.0510510103

Morán, I., Akerman, J., van de Bunt, M., Xie, R., Benazra, M., Nannmo, T., et al. (2012). Human β-cell transcriptome analysis uncovers lncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes. *Cell Metab.* 16, 435–448. doi: 10.1016/j.cmet.2012.08.010

Nakagawa, S., Ip, J. Y., Shiio, G., Tripathi, V., Zong, X., Hirose, T., et al. (2012). Malat1 is not an essential component of nuclear speckles in mice. *RNA* 18, 1487–1499. doi: 10.1261/rna.032171.112

Nesterova, T. B., Slobodyanuk, Y. S., Elisaphenko, E. A., Shevchenko, A. I., Johnstone, C., Pavlova, M. E., et al. (2001). Characterization of the genomic Xist locus in rodents reveals conservation of overall gene structure and tandem repeat evolution of XIST RNA. *Hum. Mol. Genet.* 10, 833–849. doi: 10.1093/hmg/ddi179

Ravelli, A. C., van der Meulen, J. H., Michels, R. P., Osmond, C., Barker, D. J., Hales, C. N., et al. (1998). Glycated albumin in the United Kingdom families study: associations with parental diabetes and birthweight. *BMJ* 316, 1316–1320. doi: 10.1136/bmj.316.7139.1316

Rinn, J. L., Chang, H. Y. (2012). Genome regulation by long noncoding RNAs. *Annu. Rev. Biochem.* 81, 145–166. doi: 10.1146/annurev-biochem-053110-135607

Rivas, A. L., van der Meulen, J. H., Michels, R. P., Osmond, C., Barker, D. J., Hales, C. N., et al. (1998). Glycated albumin in the United Kingdom families study: associations with parental diabetes and birthweight. *BMJ* 316, 1316–1320. doi: 10.1136/bmj.316.7139.1316

Rinn, J. L., Kertesz, M., Wang, J. K., Squazzo, S. L., Xu, X., Brugmann, S. A., et al. (2007). Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. *Cell* 131, 1319–1323. doi: 10.1016/j.cell.2007.05.022

Roseboom, T., de Rooij, S., and Painter, R. (2006). The Dutch famine and its long-term consequences for adult health. *Early Hum. Dev.* 82, 485–491. doi: 10.1016/j.earlhumdev.2006.07.001

Roseneng, A. H., Braun, M., Mahdi, T., Andersson, S. A., Travas, M. E., Shigeto, M., et al. (2012). Reduced insulin exocytosis in human pancreatic β-cells with gene
variants linked to type 2 diabetes. Diabetes 61, 1726–1733. doi: 10.2337/db11-1516
Schmidt, J. V., Matteson, P. G., Jones, B. K., Guan, X. J., and Tâghman, S. M. (2000). The Dlk1 and Gt2c genes are linked and reciprocally imprinted. Genes Dev. 14, 1997–2002. doi: 10.1101/gad.14.16.1997
Segré, A. V., DIAGRAM Consortium, MAGIC investigators, Groop, L., Mootha, V. K., Daly, M. J., et al. (2010). Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet. 6:e1001058. doi: 10.1371/journal.pgen.1001058
Seitz, H., Royo, H., Bortolin, M.-L., Lin, S.-P., Ferguson-Smith, A. C., and Cavaille, J. (2004). A large imprinted microRNA gene cluster at the mouse Dlk1-Gt2c locus. Genome Res. 14, 1741–1748. doi: 10.1101/gr.2743304
Sekita, Y., Watanasima, N., Nakamura, K., Ono, R., Kagemi, M., Wakisaka, N., et al. (2008). Role of retrotransposon-derived imprinted gene, Rill, in the feto-maternal interface of mouse placenta. Nat. Genet. 40, 243–248. doi: 10.1038/ng.2007.51
Shields, J. P., Gardner, R. J., Wadsworth, E. J., Whiteford, M. L., James, R. S., Robinson, D. O., et al. (2007). Apatiopathy and genetic basis of neonatal diabetes. Arch. Dis. Child. Fetal Neonatal Ed. 92, F193–F204. doi: 10.1136/adc.2006.114060
Small, K. S., Pedersen, H. C., Grundberg, E., Nica, A. C., Thorleifsson, G., Kong, A., et al. (2011). Identification of an imprinted master transcription regulator at the Klf14 locus related to multiple metabolic phenotypes. Nat. Genet. 43, 561–564. doi: 10.1038/ng.835
Smas, C. M., and Sul, H. S. (1993). Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 73, 725–734. doi: 10.1016/0092-8674(93)90252-L
Spengler, D., Villalba, M., Hoffmann, A., Pantalone, C., Houssami, S., Bockert, J., et al. (1997). Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain. EMBO J. 16, 2814–2825. doi: 10.1093/embomolendo/16.10.2814
Stadnick, M. P., Pieracci, E. M., Cranston, M. J., Taksel, E., Thorvaldsen, J. L., and Bartolomei, M. S. (1999). Role of a 461-bp G-rich repetitive element in H19 transgene imprinting. Dev. Genes Evol. 209, 239–248. doi: 10.1002/deg.200700248
Stadtfeld, M., Apostolou, E., Akutsu, H., Fukuda, A., Follett, P., Natesan, S., et al. (2010). Aberrant silencing of imprinted genes on chromosome 12qF1 in standing of the etiopathogenesis of diabetes. J. Cell Sci. 123, 1726–1733. doi: 10.1242/jcs.071274
Stamper, A., ZeRuth, G. T., Takeda, Y., and Jentz, A. M. (2013). The Krüppel-like protein Gli-3 similar 3 (Gli3) functions as a key regulator of insulin transcription. Mol. Endocrinol. 27, 1692–1705. doi: 10.1210/me.2013-1117
Stagljar, I., Karsunky, H., and Sonnichsen, D. F. (2013). The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol. Cell 51, 925–938. doi: 10.1016/j.molcel.2013.08.011
Stadtfeld, M., Apostolou, E., Akutsu, H., Fukuda, A., Follett, P., Natesan, S., et al. (2011). ncRNA- and Pc2 methylation-dependent gene relocation between some 14q32.2 alters susceptibility to type 1 diabetes. Nat. Genet. 43, 1741–1748. doi: 10.1038/ng.2007.609
Wallace, C., Smyth, D. J., Maisuria-Armer, M., Walker, N. M., Todd, J. A., and Clayton, D. G. (2010). The imprinted Dlk1-Meg3 gene region on chromosome 14q22.2 alters susceptibility to type 1 diabetes. Nat. Genet. 42, 68–71. doi: 10.1038/ng.693
Weinmann, L., Höck, I., Iavecic, T., Ohrt, T., Müthe, J., Schwille, P., et al. (2009). Importin 8 is a gene silencing factor that targets argonaute proteins to distinct mRNAs. Cell 136, 496–507. doi: 10.1016/j.cell.2008.12.023
Yada, T., Sakurada, M., Ihida, K., Nakata, M., Murata, F., Arimura, A., and Inagami, T. (1994). Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. J. Biol. Chem. 269, 1290–1293.
Yang, L., Qin, C., Liu, W., Zhang, J., Ohgi, K. A., Grinstein, J. D., et al. (2011). The IncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep. 2, 111–123. doi: 10.1016/j.celrep.2012.06.003
Yamane, T., Nakayama, K., Horikawa, Y., Hara, K., Osawa, H., Furuta, T., et al. (2008). Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat. Genet. 40, 1092–1097. doi: 10.1038/ng.207
Zeleuthin, G. T., Takeda, Y., and Jentz, A. M. (2013). The Krüppel-like protein Gli similars 3 (Gli3s) functions as a key regulator of insulin transcription. Mol. Endocrinol. 27, 1692–1705. doi: 10.1210/me.2013-1117
Zhong, B., Gao, C., Mao, Y. S., Lazar, Z., and Hung, G. (2012). The IncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep. 2, 111–123. doi: 10.1016/j.celrep.2012.06.003
Zhong, X., Zeita, M. J., Wang, H., Niu, B., Ge, S., Li, W., et al. (2014). Long noncoding RNA-mediated intrachromosomal interactions promote imprinting at the Kcnq1 locus. J. Cell Biol. 204, 61–75. doi: 10.1083/jcb.201304152
Zhao, J., Dahle, D., Zhou, X., Zhang, X., and Kilbanski, A. (2005). Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J. Clin. Endocrinol. Metab. 90, 2179–2186. doi: 10.1210/jc.2004-1848
Zhao, J., Ohsumi, T. K., Kung, J. T., Ogawa, Y., Grau, D. J., Sarma, K., et al. (2010). Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol. Cell 40, 939–953. doi: 10.1016/j.molcel.2010.12.011
Zhou, Y., Zheng, X., and Kilbanski, A. (2012). MEG3 noncoding RNA: a tumor suppressor. J. Mol. Endocrinol. 48, R5–R33. doi: 10.1530/JME-12-0008
Zhou, Y., Zhao, Y., Wang, Y., Zhang, X., Batista, D. L., Geijn, R., et al. (2007). Activation of p53 by MEG3 non-coding RNA. J. Biol. Chem. 282, 24731–24742. doi: 10.1074/jbc.M702092000
Zimmet, P., Alberti, K. G., and Shaw, J. (2001). Global and societal implications of the epidemic of diabetes. Nature 414, 782–787. doi: 10.1038/35022622
Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
